Dear reader, the pharmaceutical industry plays a crucial role in protecting human health, which necessitates stringent ...

This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...

Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

The US FDA has approved Wegovy pill, the first oral GLP-1 drug for weight loss. With Ozempic already in India, experts say this signals a major shift in obesity care, raising hopes, questions on ...

Minneapolis Mayor Jacob Frey said the officer who fatally shot a motorist acted recklessly and rejected federal officials' ...